29 related results for Doubled risk of acute MI in real world AF patients receiving DOACs or aspirin vs. VKA

ESC GRAND DEBATE | Aspirin for life

News 19-9-2017
ESC 2017 One of the ESC Grand Debates revolved around whether or not aspirin should be used for primary and/or secondary CV prevention. Yes, there is a lot of evidence, but how valid is that evidence? Read an impression of the debate.

Early risk factor-driven upstream therapy can prevention of progression atrial fibrillation

News 9-9-2017
ESC 2017 Data from the RACE 3 trial showed effective, feasible and safe risk factor-driven upstream therapy compared to conventional therapy for maintaining sinus rhythm in atrial fibrillation.

HF patients in sinus rhythm, but not with AF, benefit from reducing heart rate

News 1-5-2017
ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.

What do the 2016 ESC guidelines on atrial fibrillation say and what are the implications for primary care?

News 31-3-2017
EPCCS 2017 Impression of the lecture at the EPCCS CV Summit, given by dr. Geert-Jan Geersing (Utrecht, The Netherlands).

No role for aspirin in long-term prevention of recurrent VTE

News 21-3-2017
ACC 2017 In the EINSTEIN CHOICE study, rivaroxaban, at both 20 mg and 10 mg doses, was more effective than aspirin for the prevention of recurrent venous thromboembolism after 6 to 12 months of therapy.

New ESC guidelines on atrial fibrillation, in collaboration with EACTS

News 27-10-2016
The ESC, in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), published new guidelines on atrial fibrillation, which are also endorsed by the European Stroke Organisation (ESO).

EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care

News 6-9-2016
General practitioners representing various European countries discussed recent developments in the SPAF field, and specific implications for primary care in an expert meeting. This meeting resulted in a practical guidance for European GPs.

EPCCS well represented at WONCA congress

News 28-6-2016
Representatives of the EPCCS board organised three well-attended sessions at WONCA Europe 2016 in Copenhagen, Denmark, covering topics ranging from heart failure to the pros and cons of statins.

EHRA practical guide for non-vitamin K antagonist anticoagulants in non-valvular AF patients updated

News 15-6-2016
The European Heart Rhythm Association (EHRA) published a rewritten, updated version of the previously published (2013) guidelines for NOACs in non-valvular AF patients.

Patients with atrial fibrillation can benefit from yoga

News 14-3-2016
A randomised trial in patients with paroxysmal atrial fibrillation, shows that yoga improves quality of life, when practised in addition to standard medical treatment. Heart rate and blood pressure also decreased in patients who did yoga.

AHA review of evidence sex-specific characteristics of acute MI in women

News 26-1-2016
CVD morbidity and mortality in women is higher than in men, but CHD remains underdiagnosed and undertreated in women. This statement reviews the available evidence on sex-specific characteristics and mechanisms of AMI in women.

German AFNET and EHRA lay out roadmap to improve AF management

News 19-10-2015
Many people have undiagnosed and therefore untreated AF, associated with high risk of strokes and death. AFNET and EHRA composed recommendations aimed to improve AF diagnosis and treatment.

Next step on the way to approval of first antidote to anticoagulant effect of NOAC

News 28-9-2015
Following accelerated assessment, EMAs CHMP recommends granting a marketing authorisation for idarucizumab, a reversal agent for dabigatran, given its potential to respond to an unmet medical need.

Online Learning - EPCCS SPAF Consensus Document

News 6-8-2015
PeerVoice Education developed a learning activity about the EPCCS SPAF Consensus Document: "Expert Insights on EPCCS Recommendations for Stroke Prevention in Atrial Fibrillation: What General Practitioners Need to Know".

Consensus paper on arrhythmia management from a patient preference perspective

News 25-6-2015
European and international experts reviewed the evidence on patient values and preferences in the management of cardiac tachyarrhythmias and advise on best practice.

Anticoagulant edoxaban receives positive CHMP opinion for management of atrial fibrillation and venous thromboembolism

News 26-4-2015
CHMP recommends for direct inhibitor of factor Xa edoxaban to be granted marketing authorisation for prevention of stroke and systemic embolism in AF and the prevention and treatment of VTE.

If anticoagulation and platelet inhibition is too strong for too long, risk of dementia increases

News 18-11-2014
AHA 2014 Patients with atrial fibrillation who had supratherapeutic INR >25% of the time, had a higher risk of dementia, possibly through brain damage due to microbleeds.

Primary CV prevention with low-dose aspirin was not effective in Japanese elderly

News 17-11-2014
AHA 2014  Daily aspirin 100 mg did not reduce the general risk of atherosclerotic events in elderly Japanese patients with CV risk factors.

Antidote for Factor Xa inhibitor shows positive results in phase III study

News 6-10-2014
The first Phase 3 study of Factor Xa inhibitor antidote andexanet alfa, met its primary and secondary endpoints and shows well-tolerated and effective reversal of anticoagulation activity of apixaban.

Prof. dr. Freek Verheugt: “Role of aspirin in cancer mortality far from clear”

News 21-8-2014
Prof. dr. F.W.A. Verheugt (Amsterdam) responds to an article in Ann Oncol of this week about the effect of prophylactic aspirin use with regard to cancer and CVD events.

A more nuanced view from the clinic on the critical BMJ publications about dabigatran

News 19-8-2014
Dr. Michiel Coppens (vascular medicine, Academic Medical Center, Amsterdam, NL) shares his views on the critical publications in BMJ about the safety of using dabigatran.

BMJ criticises safety and use of dabigatran

News 18-8-2014
British Medical Journal writes that information has been withheld about the importance of monitoring plasma levels of dabigatran. We summarise the critic and the producer's response.

Net benefit for cancer and CVD of long-term aspirin use as primary prevention

News 11-8-2014
Prophylactic aspirin use for at least 5 years at doses between 75 and 325 mg/day seems to have a favourable benefit-harm profile, with regard to cancer and CVD events.

European approval of apixaban for treatment and prevention of recurrent DVT and PE

News 4-8-2014
The efficacy and safety of apixaban in the treatment of recurrent VTE/VTE-related death had been demonstrated in clinical trials AMPLIFY and AMPLIFY-NXT.

European approval for dabigatran for treatment of deep venous trombosis and pulmonary embolism

News 22-6-2014
The European Commission approved dabigatran etexilate for treatment of deep venous thrombosis and pulmonary embolism, and prevention of recurrent DVT and PE.

Sports & the heart: beneficial without limits?

News 20-5-2014
Exercise is good for the heart, but an overkill could be bad for healthy adults and patients with CVD, according to two observational studies suggesting a J-shaped curve for the dose-response effects of intense physical activity.

FDA: aspirin should not be used as primary prevention of myocardial infarction and stroke

News 4-5-2014
The FDA has announced that aspirin should not be marketed for the prevention of a first myocardial infarction or stroke in people without cardiovascular disease.

FDA grants investigational Factor Xa inhibitor antidote breakthrough therapy designation

News 26-11-2013
This FDA designation should expedite the development of andexanet alfa, which has been shown to quickly reverse the anticoagulant activity of Factor Xa inhibitors in phase 2 studies.

Dabigatran summary. Meta-analysis of noninferiority randomized controlled trials

News 18-4-2012
This analysis is driven primarily by the RE-LY trial,(1) which contributes 75% of the weight to the overall effect size. It is noteworthy that the results are rendered non-significant (OR 1.16; 95%CI 0.69 to 1.94) when RE-LY is excluded from the analysis.

Upcoming meetings

EPCCS Council Meeting December 6-7, 2017, Stratford Upon Avon, United Kingdom
10th EPCCS Annual CV Summit for Primary care March 15-16, 2018, Malaga, Spain
All upcoming meetings...

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...